Adoption of the income statements and the balance sheets
The Annual General Meeting approved the income statements and the balance sheets for the fiscal year 2021.
The Annual General Meeting resolved, in accordance with the proposal of the Board of Directors that no dividend should be paid for the fiscal year 2021.
The Annual General Meeting discharged the Board members and the Chief Executive Officer from liability for the fiscal year 2021.
Board of Directors
In accordance with the proposal of the Nomination Committee, the Annual General Meeting resolved that the Board of Directors shall consist of four persons and no deputies.
The Annual General Meeting resolved on re-election of Mattias Klintemar and Nikolaj Sörensen as well as new election of Kerstin Valinder Strinnholm and
The Annual General Meeting resolved on re-election of
The Annual General Meeting resolved, in accordance with the proposal of the Nomination Committee, that an aggregate annual fee of
Fees to the Auditors, for a period until the end of the next Annual General Meeting, are to be paid as per approved invoice.
Nomination Committee
The Annual General Meeting resolved, in accordance with the proposal of the Nomination Committee, that the Company shall have a Nomination Committee consisting of four members. The Nomination Committee shall comprise one representative of each of the three largest shareholders or owner groups in the Company in terms of votes as per
Principles for remuneration
The Annual General Meeting resolved to approve the
Remuneration report
The Annual General Meeting resolved to approve the
Implementation of LTI 2022
The Annual General Meeting also resolved to approve the
Authorization to issue shares
The Annual General Meeting resolved, in accordance with the proposal of the Board of Directors, to authorize the Board of Directors to, within the scope of the articles of association, with or without deviation from the shareholders' pre-emptive rights, on one or several occasions during the period until the next Annual General Meeting, resolve to increase the Company's share capital by issuing new shares in the Company. The total number of shares issued in accordance with this authorisation may be equivalent to a maximum of twenty (20) per cent of the shares in the Company at the time of the Annual General Meeting.
The Annual General Meeting authorized the Board of Directors, the CEO or whomever the Board of Directors appoints, to make such minor adjustments and clarifications regarding the Annual General Meeting's resolution that may prove necessary in connection with the registration with the Companies Registration Office and
Minutes from the meeting and complete resolutions
The minutes from the Annual General Meeting will be made available at the Company and on the Company's website, www.mobergpharma.se.
Post voting procedure
To prevent the spread of the virus that causes Covid-19, the Extraordinary General Meeting was conducted via a post voting procedure and thus without physical presence of shareholders, proxies or external parties.
For additional information, please contact:
About this information
The information was submitted for publication at
About
https://news.cision.com/moberg-pharma/r/bulletin-from-moberg-pharma-s-agm-on-may-16-th--2022,c3567814
https://mb.cision.com/Main/1662/3567814/1580282.pdf
(c) 2022 Cision. All rights reserved., source